IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: ISIS-GCGRRx - Dose Level 1Drug: PlaceboDrug: ISIS-GCGRRx - Dose Level 2
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01885260
- Locations
- 🇿🇦
Isis Investigational Site, Western Cape, South Africa
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
- Conditions
- FAPFamilial Amyloid PolyneuropathyTTRAmyloidosisTransthyretin
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT01737398
- Locations
- 🇵🇹
CHP-HGSA, Unidade Clinica de Paramiloidose, Porto, Portugal
🇩🇪UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin, Munster, Germany
🇪🇸Hospital Universitari Vall D' Hebron, Barcelona, Spain
Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT01713361
- Locations
- 🇺🇦
Isis Investigational Site, Sevastopol, Ukraine
Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- Drug: ISIS CRP RxDrug: Placebo
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01710852
- Locations
- 🇬🇧
Eastbourne General Hospital - Cardiology Department, Eastbourne, East Sussex, United Kingdom
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: PlaceboDrug: ISIS-APOCIIIRX
- First Posted Date
- 2012-07-23
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01647308
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01563302
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: ISIS apoC-III RxDrug: Placebo
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT01529424
- Locations
- 🇺🇸
Physicians East, Quadrangle Medical Specialists, Greenville, North Carolina, United States
🇺🇸Eastern Carolina Physicians, Kinston, North Carolina, United States
🇺🇸Natalie A Doyle, MD PA, Wilson, North Carolina, United States
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: ISIS CRP Rx or Placebo
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01414101
- Locations
- 🇷🇺
Isis Investigational Site, Saint Petersburg, Russian Federation
🇨🇦Isis Investigational site, Kamloops, British Columbia, Canada
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT01234038
- Locations
- 🇵🇱
Alojzy Pawelec Provincial Hospital of Lung Diseases, Wodzislaw Slaski, Poland
🇭🇺Semmelweis University Faculty of Medicine, Budapest, Hungary
🇵🇱Independent Public Teaching Hospital No. 4 In Lublin, Lublin, Poland
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
- Conditions
- Castrate-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT01234025
- Locations
- 🇺🇸
Fort Range Cancer Center, Fort Collins, Colorado, United States
🇺🇸St. Luke's - Roosevelt Hospital Center, New York, New York, United States
🇵🇱Clinical Oncology Department and Day Hospitalization Unit, Independent Public Healthcare Facility T. Koszarowski Opolskie Oncology Centre in Opole, Opole, Poland